OSR (NASDAQ:OSRH) Shares Down 25.1% – What’s Next?

OSR Holdings, Inc. (NASDAQ:OSRH)’s share price dropped 25.1% during mid-day trading on Wednesday . The company traded as low as $0.2507 and last traded at $0.2890. Approximately 2,807,246 shares were traded during trading, an increase of 329% from the average daily volume of 654,724 shares. The stock had previously closed at $0.3860.

Analyst Ratings Changes

Several equities research analysts have recently commented on OSRH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a report on Wednesday, June 24th. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, OSR has an average rating of “Sell”.

OSR Trading Down 25.1%

The firm’s 50-day simple moving average is $0.39 and its two-hundred day simple moving average is $0.48. The stock has a market capitalization of $10.15 million, a PE ratio of -0.88 and a beta of 0.56.

OSR (NASDAQ:OSRH) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter. OSR had a negative return on equity of 7.24% and a negative net margin of 363.26%.The business had revenue of $0.48 million during the quarter.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. Institutional investors own 55.30% of the company’s stock.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.